BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hyrich KL, Symmons DP, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 2006;54:2701-2702. [PMID: 16871549 DOI: 10.1002/art.22028] [Cited by in Crossref: 80] [Cited by in F6Publishing: 61] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. [PMID: 17916445 DOI: 10.1016/j.clim.2007.08.012] [Cited by in Crossref: 156] [Cited by in F6Publishing: 141] [Article Influence: 11.1] [Reference Citation Analysis]
2 O’Donnell S, O’Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther. 2008;27:885-894. [PMID: 18284649 DOI: 10.1111/j.1365-2036.2008.03648.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
3 Østensen M. Therapy: are TNF inhibitors safe in pregnancy? Nat Rev Rheumatol 2009;5:184-5. [PMID: 19337279 DOI: 10.1038/nrrheum.2009.47] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 10.5] [Reference Citation Analysis]
5 Paschou S, Voulgari PV, Vrabie IG, Saougou IG, Drosos AA. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol. 2009;36:351-354. [PMID: 19040305 DOI: 10.3899/jrheum.080554] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
6 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
7 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
8 Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, Azaïs I, Martin A, Pallot-Prades B, Maugars Y. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76:28-34. [PMID: 19059799 DOI: 10.1016/j.jbspin.2008.04.016] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 6.4] [Reference Citation Analysis]
9 Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 2006;6:1349-60. [PMID: 17223742 DOI: 10.1517/14712598.6.12.1349] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
10 Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209. [PMID: 16712713 DOI: 10.1186/ar1957] [Cited by in Crossref: 350] [Cited by in F6Publishing: 256] [Article Influence: 23.3] [Reference Citation Analysis]
11 Laws PM, Young HS. Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol 2010;3:25-37. [PMID: 21437057 DOI: 10.2147/ccid.s6497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, Masson P, De Keyser F. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50:1955-1968. [PMID: 21890617 DOI: 10.1093/rheumatology/ker302] [Cited by in Crossref: 80] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
13 Chiam NP, Lim LL. Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol 2014;2014:401915. [PMID: 24683491 DOI: 10.1155/2014/401915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
14 Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16:881-895. [PMID: 19885906 DOI: 10.1002/ibd.21154] [Cited by in Crossref: 102] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
15 Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology 2015;11:709-20. [DOI: 10.1586/1744666x.2015.1037742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
16 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
17 Dagli AI, Lee PJ, Correia CE, Rodriguez C, Bhattacharya K, Steinkrauss L, Stanley CA, Weinstein DA. Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveries. J Inherit Metab Dis 2010;33 Suppl 3:S151-7. [PMID: 20386986 DOI: 10.1007/s10545-010-9054-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
18 Saougou I, Markatseli TE, Papagoras C, Kaltsonoudis E, Voulgari PV, Drosos AA. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine 2013;80:34-7. [PMID: 22575067 DOI: 10.1016/j.jbspin.2012.03.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
19 Osting VC, Carter JD. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf. 2010;9:421-429. [PMID: 20367495 DOI: 10.1517/14740330903578639] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
20 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Falgarone G, Duclos M, Boissier M. TNFα antagonists in rheumatoid arthritis patients seen in everyday practice. Joint Bone Spine 2007;74:523-6. [DOI: 10.1016/j.jbspin.2007.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
22 Dubertret L, Chimenti S, Christophers E, Daudén E, de Rie M, Griffiths CEM, Kragballe K, Ståhle M, Stingl G. Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. British Journal of Dermatology 2009;161:1-30. [DOI: 10.1111/j.1365-2133.2009.09173.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
23 Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010;37:9-17. [PMID: 20008917 DOI: 10.3899/jrheum.090563] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
24 Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36:635-641. [PMID: 19132789 DOI: 10.3899/jrheum.080545] [Cited by in Crossref: 195] [Cited by in F6Publishing: 137] [Article Influence: 16.3] [Reference Citation Analysis]
25 Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Modern Rheumatology 2014;17:451-8. [DOI: 10.3109/s10165-007-0626-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
26 Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;142:e1S-e111S. [PMID: 23131960 DOI: 10.1378/chest.12-1044] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
27 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
28 Kuriya B, Hernández-díaz S, Liu J, Bermas BL, Daniel G, Solomon DH. Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res 2011;63:721-8. [DOI: 10.1002/acr.20422] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
29 Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823-826. [PMID: 21362710 DOI: 10.1136/ard.2010.140822] [Cited by in Crossref: 125] [Cited by in F6Publishing: 98] [Article Influence: 12.5] [Reference Citation Analysis]
30 Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5:382-390. [PMID: 19506586 DOI: 10.1038/nrrheum.2009.103] [Cited by in Crossref: 91] [Cited by in F6Publishing: 70] [Article Influence: 7.6] [Reference Citation Analysis]
31 Carvalheiras G, Faria R, Braga J, Vasconcelos C. Fetal outcome in autoimmune diseases. Autoimmunity Reviews 2012;11:A520-30. [DOI: 10.1016/j.autrev.2011.12.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
32 Makol A, Wright K, Amin S. Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management. Drugs 2011;71:1973-87. [DOI: 10.2165/11596240-000000000-00000] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
33 Cobo-Ibáñez T, Martín-Mola E. Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis. Expert Opin Pharmacother 2007;8:1373-97. [PMID: 17563271 DOI: 10.1517/14656566.8.9.1373] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
34 Hyrich KL, Watson KD, Isenberg DA, Symmons DPM; on behalf of the BSR Biologics Register. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3. [DOI: 10.1093/rheumatology/ken242] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
35 Chee MM, Alcorn N, Paterson K, Madhok R. Promoting science over serendipity in prescribing anti-TNF therapy. Rheumatology 2009;48:865-6. [DOI: 10.1093/rheumatology/kep095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
37 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591-2602. [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
38 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
39 Grotting LA, Papaliodis GN. A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy. Semin Ophthalmol 2017;32:75-81. [PMID: 27805464 DOI: 10.1080/08820538.2016.1228402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Borrego L. Etanercept en el embarazo y lactancia. Actas Dermo-Sifiliográficas 2010;101:97-101. [DOI: 10.1016/s0001-7310(10)70016-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
41 Narula N, Al-dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2014;20:1862-9. [DOI: 10.1097/mib.0000000000000092] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
42 Viktil KK, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy-a population-based cohort study. Pharmacoepidem Drug Safe 2009;18:737-42. [DOI: 10.1002/pds.1775] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
43 Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. Journal of the American Academy of Dermatology 2008;59:295-315. [DOI: 10.1016/j.jaad.2008.03.018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
44 Salmon JE, Alpert D. Are we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 2006;54:2353-5. [DOI: 10.1002/art.22027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
45 Leman J, Burden A. Treatment of severe psoriasis with infliximab. Ther Clin Risk Manag 2008;4:1165-76. [PMID: 19337424 DOI: 10.2147/tcrm.s3094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Skomsvoll JF, Wallenius M, Koksvik HS, Rødevand E, Salvesen KA, Spigset O, Kvien TK. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol. 2007;3:156-164. [PMID: 17334338 DOI: 10.1038/ncprheum0426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
47 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
48 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Nguyen TU, Koo J. Etanercept in the treatment of plaque psoriasis. Clin Cosmet Investig Dermatol 2009;2:77-84. [PMID: 21436970 DOI: 10.2147/ccid.s3412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Cassina M, Fabris L, Okolicsanyi L, Gervasi MT, Memmo A, Tiboni GM, Di Gianantonio E, Clementi M. Therapy of inflammatory bowel diseases in pregnancy and lactation. Expert Opinion on Drug Safety 2009;8:695-707. [DOI: 10.1517/14740330903357463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
51 Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007;8:2089-107. [PMID: 17714062 DOI: 10.1517/14656566.8.13.2089] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
52 Østensen M. Management of early aggressive rheumatoid arthritis during pregnancy and lactation. Expert Opinion on Pharmacotherapy 2009;10:1469-79. [DOI: 10.1517/14656560902980194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
53 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Journal of the American Academy of Dermatology 2019;80:43-53. [DOI: 10.1016/j.jaad.2018.06.056] [Cited by in Crossref: 119] [Cited by in F6Publishing: 83] [Article Influence: 59.5] [Reference Citation Analysis]
54 Rump JA, Schönborn H. [Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment]. Z Rheumatol. 2010;69:903-909. [PMID: 20532789 DOI: 10.1007/s00393-010-0652-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
55 Lockshin MD. Treating rheumatic diseases in pregnancy: dos and don'ts. Ann Rheum Dis 2006;65 Suppl 3:iii58-60. [PMID: 17038475 DOI: 10.1136/ard.2006.058420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
56 Elliott AB, Chakravarty EF. Immunosuppressive Medications during Pregnancy and Lactation in Women with Autoimmune Diseases. Womens Health (Lond Engl) 2010;6:431-42. [DOI: 10.2217/whe.10.24] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
57 Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019. [PMID: 19857207 DOI: 10.1111/j.1365-2133.2009.09505.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 238] [Article Influence: 28.0] [Reference Citation Analysis]
58 Dessinioti C, Stefanaki I, Stratigos AJ, Kostaki M, Katsambas A, Antoniou C. Pregnancy during adalimumab use for psoriasis. J Eur Acad Dermatol Venereol. 2011;25:738-739. [PMID: 20569288 DOI: 10.1111/j.1468-3083.2010.03756.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
59 Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-97. [PMID: 21621603 DOI: 10.1016/j.reprotox.2011.05.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
60 Winger EE, Reed JL. ORIGINAL ARTICLE: Treatment with Tumor Necrosis Factor Inhibitors and Intravenous Immunoglobulin Improves Live Birth Rates in Women with Recurrent Spontaneous Abortion: TNFα INHIBITORS FOR RSA. American Journal of Reproductive Immunology 2008;60:8-16. [DOI: 10.1111/j.1600-0897.2008.00585.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 87] [Article Influence: 8.2] [Reference Citation Analysis]
61 Offiah M, Brodell RT, Campbell LR, Wyatt JP. Collodion-like membrane in a newborn exposed to infliximab. J Am Acad Dermatol. 2014;71:e22-e23. [PMID: 24947707 DOI: 10.1016/j.jaad.2014.01.856] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]